Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 5/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13840449 | 0.76 | NPY5R (0.46) | PTGDR2RORCP2RX3NPY5RMEN1 | |
| SCHEMBL13840442 | 0.74 | MAPT (0.62) | RORCMAPTNPY5RNPSR1MEN1 | |
| SCHEMBL6753270 | 0.69 | PTGDR2 (0.47) | PTGDR2RORCP2RX3MAPTNPY5R | |
| SCHEMBL13840444 | 0.68 | KMT2A (0.43) | JAK1MAPTNPSR1MEN1GAA | |
| SCHEMBL10113929 | 0.68 | MAPT (0.59) | RORCMAPTNPY5RNPSR1MEN1 | |
| SCHEMBL13840440 | 0.67 | KMT2A (0.43) | JAK1MAPTNPSR1MEN1GAA | |
| SCHEMBL13484159 | 0.66 | MAPT (0.50) | JAK1MAPTNPSR1MEN1GAA | |
| SCHEMBL2601692 | 0.66 | TP53 (0.40) | GNRHRMAPT | |
| SCHEMBL13840446 | 0.66 | MEN1 (0.44) | JAK1MAPTNPSR1MEN1GAA | |
| SCHEMBL10114873 | 0.66 | NPC1 (0.48) | RORCMAPTNPSR1MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534892-B2 | Sulfonamide compound | SHIONOGI & CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534892-B2 | Sulfonamide compound | SHIONOGI & CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070287710-A1 | Piperidinediyl-containing sulfonamide; NPY Y5 receptor antagonist activity; antiobesity agent or anorectic agent | SHIONOGI & CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070287710-A1 | Piperidinediyl-containing sulfonamide; NPY Y5 receptor antagonist activity; antiobesity agent or anorectic agent | SHIONOGI & CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287710-A1 | Piperidinediyl-containing sulfonamide; NPY Y5 receptor antagonist activity; antiobesity agent or anorectic agent | NPY5R, NPY1R, NPY2R | GNRHR 55/4885PTGDR2 314/4885RORC 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.